Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Blood coagulation system analyzer, blood coagulation system analysis method and program

A blood coagulation system and analyzer technology, applied in the field of blood coagulation system analyzer, blood coagulation system analysis and program, can solve the problems of increasing the risk of bleeding

Active Publication Date: 2014-12-10
SONY CORP
View PDF6 Cites 19 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] In the prophylactic administration of antiplatelet aggregation drugs or anticoagulants against thrombosis, there is a side effect of excessive doses that increase the risk of bleeding

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Blood coagulation system analyzer, blood coagulation system analysis method and program
  • Blood coagulation system analyzer, blood coagulation system analysis method and program
  • Blood coagulation system analyzer, blood coagulation system analysis method and program

Examples

Experimental program
Comparison scheme
Effect test

experiment example A

[0101] In Experimental Example A, reference values ​​were set from each of the measured values ​​of healthy subjects and hospitalized patients with respiratory diseases (hereinafter referred to as "patients with respiratory diseases").

[0102] A-1. Regarding blood sampling and diseases

[0103] The inventors of the present disclosure collected blood from healthy subjects by using a vacuum blood collection tube treated with sodium citrate as an anticoagulant. This will be a whole blood sample from a healthy subject. In the same manner, the inventors of the present disclosure collected blood from a patient suffering from a respiratory disease while the patient was hospitalized. This would be a whole blood sample from a patient with a respiratory disease.

[0104] Susceptibility in patients with respiratory diseases is classified herein into interstitial pneumonia (IP), lung cancer (LK), chronic obstructive pulmonary disease (COPD), collagen vascular disease (CVD), sleep apnea...

experiment example B

[0130] In Experimental Example B, reference values ​​were set in the field of surgery, and particularly by the cases of DVT and PE episodes after artificial knee replacement.

[0131] B-1. Regarding blood sampling and diseases

[0132] Knee replacement is a surgery that carries a very high risk of deep vein thrombosis (DVT) after surgery. On the morning of the day of surgery (before surgery) and on the day after surgery (after surgery), blood was collected from the patient by using a vacuum blood collection tube treated with sodium citrate as an anticoagulant, and the blood was used for measurement . Examination of the onset time of DVT was performed by ultrasonography 4-5 days after surgery. In the same manner, blood was collected from healthy subjects by using a vacuum blood collection tube treated with sodium citrate as an anticoagulant, and the blood was used for measurement.

[0133] B-2. Dielectric measurement

[0134] The inventors of the present disclosure added a ...

experiment example C

[0146] Experimental Example C will describe drug monitoring in patients with diabetes.

[0147] C-1. Experimental method

[0148] The inventors of the present disclosure performed studies using blood samples collected from healthy subjects and patients with diabetes, respectively. During blood collection, blood was collected from healthy subjects by using vacuum blood collection tubes treated with sodium citrate as an anticoagulant. The inventors of the present disclosure added a 0.25 M calcium chloride aqueous solution (85 uL (microliter) per 1 mL of blood) to a blood sample whose temperature was maintained at 37° C. and started a coagulation reaction. The inventors of the present disclosure performed measurement at a measurement time interval of one minute (60 minutes in total) at a temperature of 37° C. in a frequency range of 40 Hz to 110 MHz by using an impedance analyzer (4294A) manufactured by Agilent Corporation.

[0149] C-2. Analysis of coagulation time

[0150] T...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

There is provided a blood coagulation system analyzer, including a measurement section and an analysis section. The measurement section measures a time change of impedance of a blood sample, which is obtainable by applying an alternating electric field to the blood sample. The analysis section extracts a parameter indicating the characteristics of the impedance from the measured data of the time change of the impedance. Furthermore, the analysis section analyzes a degree of enhancement of blood coagulation on the basis of a comparison of the extracted parameter with at least one reference value which defines the criteria of the enhancement of blood coagulation.

Description

technical field [0001] The present disclosure relates to an analyzer, an analysis method and a program for analyzing blood samples with coagulation system diseases. Background technique [0002] In the past, for example, prophylactic administration of antiplatelet drugs or anticoagulants was performed in patients at risk of thrombosis and healthy subjects. Patients at risk of thrombosis include, but are not limited to, patients with diabetes, atherosclerosis, cancer, heart disease, respiratory diseases, etc., perioperative patients, and patients taking immunosuppressive drugs. Additionally, healthy subjects at risk for thrombosis include pregnant women and the elderly. Acetylsalicylic acid and the like are used as anti-platelet aggregation drugs. Warfarin, heparin, activated coagulation factor X (factor Xa) inhibitors, etc. are used as anticoagulants. [0003] In the prophylactic administration of antiplatelet aggregation drugs or anticoagulants against thrombosis, excess...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G01N27/22G01N33/49G01N27/02
CPCG01N33/4905G01N27/026G01N27/02G01N27/221G01N27/06G01N33/48707
Inventor 林义人马克-奥雷勒·布兰内村功
Owner SONY CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com